Please login to the form below
Antoni Villaró joins Ferrer as chief operating officer
He will report to the Spanish pharmaceutical company's CEO Jordi Ramentol
Spanish pharmaceutical company Ferrer has appointed Antoni Villaró as its new chief operating officer.
He will report to Barcelona-based Ferrer's CEO Jordi Ramentol and joins the company from Otsuka Pharmaceutical, which he worked for nearly 15 years.
During his time at the Japanese pharma company Villaró served as president and CEO of Otsuka Europe, based in London, and spent three years on Otsuka's board of directors.
Prior to this he was CEO for Otsuka in Spain.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- FREELANCE Associate Director - Healthcare PR - Remote or London
-
Superb Day Rate &Benefits
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- AM / Senior Account Manager – Healthcare PR - London / Remote
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Omicron rise prompts tougher measures in England
- Pfizer/BioNTech promote booster against Omicron
- What is EVID AI?
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- AstraZeneca and Ionis sign $3.6bn deal for eplontersen
- Roche’s Actemra approved for severe COVID-19 in Europe
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Sanofi to buy acne specialist Origimm
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Promoting off-label use: where to draw the line?
- Synairgen’s SNG001 advances into phase 3 COVID-19 trial
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
PMHub
TRIDUCIVE
Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...
Latest intelligence
- Virtual meeting technologies for reducing emissions and waste in the healthcare industry
- ...
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
